Dapivirine
- Generic Name
- Dapivirine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19N5
- CAS Number
- 244767-67-7
- Unique Ingredient Identifier
- TCN4MG2VXS
- Background
Dapivirine has been investigated for the prevention of HIV-1 Infections and Topical Penile Exposures.
- Associated Conditions
- -
- Associated Therapies
- -
IDWeek 2024: Prevention and treatment for HIV – clinical trials and policy
Emerging HIV therapies like lenacapravir (LEN) and long-acting injectables offer new prevention and treatment options, especially for high-risk groups. Despite advancements, adherence and policy challenges, such as funding reallocations, threaten progress. Advocacy and equitable access are crucial for future HIV care.
IDWeek 2024: Prevention and treatment for HIV - clinical trials and policy challenges
Emerging therapies like lenacapravir (LEN) and long-acting injectables (LAI) offer new HIV prevention and treatment options, particularly for high-risk groups and children. However, policy challenges, such as Tennessee's rejection of CDC funding, threaten progress, emphasizing the need for equitable access and continued advocacy.
HIVR4P conference highlights latest in HIV prevention research
HIVR4P conference in Lima, Peru, highlights latest HIV prevention research, including long-acting injectables and dapivirine vaginal ring.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath